Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information
Content of the report:
The Management Board of Celon Pharma S.A. (the “Company”) hereby publishes a supplement to current report No. 35/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company's ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:
12) determination of the amount of the total costs which have been included in the issue costs:
As of the date of this report, the total costs incurred by the Company in connection with the issue of D-series shares amounted to PLN 13,358,254.97, including the costs of:
a) preparing and implementing the offer – PLN 10,499,385.06;
b) the underwriters' remuneration, separately for each underwriter – not applicable;
c) preparing of the prospectus, including costs of advisory services – PLN 2,075,140.04;
d) promoting the offer – PLN 783,729.87.
The settlement of the costs of the issue of D-series shares in the accounting books will be made by way of reducing the Company's supplementary capital.
13) The average cost of conducting the subscription per unit of security subscribed:
The average cost incurred by the Company per D-series share amounted to approximately PLN 2.23.